We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Chemical Attraction Prompts B Cell Migration

By Biotechdaily staff writers
Posted on 21 May 2002
Scientists from the University of California, San Francisco (UCSF, USA) have found that chemical attraction is the key to understanding how B cells that make antibodies find the T cells they must team up with to attack invading pathogens. More...
The research, based on studies of mice, is published in the March 7, 2002 issue of the journal Nature.

Prior to encountering foreign antigens, B cells concentrate in regions within the lymphatic system where few T cells reside (the B zone), anchored by their attraction to a type of chemical attractant, or chemokine called CXCL13. Contact with an antigen from an invading microbe triggers changes in the B cell surface resulting in the doubling of receptors on its surface cued to a different group of chemokines known as CCL19 and CCL21. These are found in far greater concentration where T cells reside (the T zone). The increased receptiveness to these signals prompts the B cells to migrate within the lymphatic tissue from the B zone to the boundary between the B and T zones where cells of the two types can pair up. The pairing is known to be essential for the immune system to mount an antibody attack.

In experiments with mice and mice cells, the researchers used a gene therapy approach to show that artificially increasing the numbers of receptors for T zone chemokines, CCL19 and CCL21, on B cells was sufficient to cause B cell migration to the T zone. Reciprocally, B cells with artificially increased receptors for the CXCL13 chemokine, overcame the attractive signals from the T zone and retreated to the B zone.

Using B cells from mice with mutations in the receptor for the T zone chemokines, the researchers showed that this receptor was essential for the re-routing behavior. B cells with increased receptors for T zone chemokines (CCL19 and CCL21) but no receptors for the B zone chemokine CXCL13 no longer took the route that ran along the boundary of the two neighborhoods, but instead headed directly toward the T zone.

The findings led to the conclusion that B cell migration is at least partially determined by the balance of responsiveness to the two kinds of chemical attractants made in adjacent zones with the B cells becoming much more responsive to being pulled toward the T zone after they are exposed to an antigen.

"We have known for some time that the antigen triggers a change that prompts B cell migration, but we did not know how the process worked,” said Jason Cyster, Ph.D., a UCSF associate professor of microbiology and immunology.

The researchers now hope to determine whether similar changes in chemokine receptor levels are involved in redirecting the movement of autoreactive B cells. If this proves to be true, they think they may be on the path to resolving what goes wrong in some people to cause autoantibody-mediated disease. Blocking these attractants may prove an effective strategy to block autoantibody mediated disease.




Related Links:
University of California, San Francisco

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.